Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cocrystal Pharma Inc (COCP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.00-0.99%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for COCP yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain sufficient funding for operations and trials | Cocrystal Pharma is advancing clinical trials for antiviral drugs. | Intact | capital runs out or highly dilutive financing needed | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, early-stage biotech thesis, not an established earnings compounder. The thesis is in a watch state: clinical work is advancing, but recent financial performance is weak and remains well below its industry cohort.
The available valuation signal is broadly aligned with peers, with medium confidence, and the evidence does not identify a clear expectations gap. The snapshot gives little detail about market expectations, so what is already assumed is uncertain.
Near term, revenue is minimal and losses persist, while an elevated risk of an earnings miss adds uncertainty. Over the multi-year view, management’s stated focus is advancing antiviral candidates; the last subject has been dosed in the norovirus trial, with topline data expected by the end of 2026-Q4. A recent private placement provides funding for clinical development, but does not remove the ongoing funding and execution risks.
A key near-term swing factor is whether the company avoids a guidance cut, which could prompt estimates to be revised lower. Over the multi-year view, the thesis depends on clinical progress and trial data, alongside continued access to funding. Broader Healthcare sector momentum is a possible support, while weakening jobs data may increase recession concerns for cyclical names.
COCP’s 1-to-3-year thesis rests on clinical advancement rather than current financial strength. Progress is visible, but persistent losses, elevated near-term risk, and uncertain clinical and funding outcomes keep the thesis fragile. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cocrystal Pharma is advancing clinical trials for antiviral drugs. |
| Intact |
| clinical development stalls or key trial failures occur |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce losses and improve earnings | A primary condition in Cocrystal Pharma Inc's published investment case. The stated target is EPS loss narrows from -$0.69 in FY26 to less negative in FY27. | Broken | EPS loss worsens or remains flat beyond FY27 | Diluted EPS: $-0.23 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$0.69 in FY26 to less negative in FY27. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 2026-0.23 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.64 → $-0.47 · observed estimates
Unavailable → Unavailable · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-25 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-26 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-27 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-28 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-29 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-30 | $-0.64 | Unavailable | 1 / 0 |
| 2026-07-31 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-01 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-02 | $-0.64 | $0 | 1 / 1 |
| 2026-08-03 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-04 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-05 | $-0.64 | $0 | 1 / 1 |
| 2026-08-06 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-07 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-08 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-09 | $-0.64 | $0 | 1 / 1 |
| 2026-08-10 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-11 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-12 | $-0.64 | $0 | 1 / 1 |
| 2026-08-13 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-14 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-15 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-16 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-17 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-18 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-19 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-20 | $-0.64 | Unavailable | 1 / 0 |
| 2026-08-21 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-22 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-23 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-24 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-25 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-26 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-27 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-28 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-29 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-30 | $-0.58 | Unavailable | 1 / 0 |
| 2026-08-31 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-01 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-02 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-03 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-04 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-05 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-06 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-07 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-08 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-09 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-10 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-11 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-12 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-13 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-14 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-15 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-16 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-17 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-18 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-19 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-20 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-21 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-22 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-23 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-24 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-25 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-26 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-27 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-28 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-29 | $-0.58 | Unavailable | 1 / 0 |
| 2026-09-30 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-01 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-02 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-03 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-04 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-05 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-06 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-07 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-08 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-09 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-10 | $-0.58 | Unavailable | 1 / 0 |
| 2026-10-11 | $-0.47 | Unavailable | 1 / 0 |
| 2026-10-12 | $-0.47 | Unavailable | 1 / 0 |
| 2026-10-13 | $-0.47 | Unavailable | 1 / 0 |
| 2026-10-14 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-15 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-16 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-17 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-18 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-19 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-20 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-21 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-22 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-23 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-24 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-25 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-26 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-27 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-28 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-29 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-30 | $-0.47 | Unavailable | 2 / 0 |
| 2026-10-31 | $-0.47 | Unavailable | 2 / 0 |
| 2026-11-01 | $-0.47 | Unavailable | 2 / 0 |
| 2026-11-02 | $-0.47 | Unavailable | 2 / 0 |
| 2026-11-03 | $-0.47 | Unavailable | 2 / 0 |
| 2026-11-04 | $-0.47 | Unavailable | 2 / 0 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.